Pricing Log in Create free account

Aligos Therapeutics, Inc. (ALGS) vs IRulya Therapeutics Inc. (IRLA)

Aligos Therapeutics, Inc. and IRulya Therapeutics Inc. are both Biotechnology companies. Aligos Therapeutics, Inc. and IRulya Therapeutics Inc. are of similar size ($29.8M and $28.2M). IRulya Therapeutics Inc. has the higher net margin (0.00% vs −197.0%) and the higher return on invested capital (0.00% vs −400.9%). Across the 12 metrics below, IRulya Therapeutics Inc. leads on 9 and Aligos Therapeutics, Inc. on 3.

Valuation

Metric ALGS IRLA Biotechnology median
P/E n/m n/m 10.60
P/S 1.27 n/m 9.40
P/B 3.78 n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 0.37 n/m 9.02
Earnings yield (155.26%) (463.25%) (32.88%)
Free cash flow yield (160.62%) (25.09%) (23.13%)

Profitability

Metric ALGS IRLA Biotechnology median
Gross margin 100.00% 0.00% 68.51%
Operating margin (215.55%) 0.00% 0.00%
Net margin (197.01%) 0.00% 0.00%
Free cash flow margin (203.21%) 0.00% 0.00%
Return on equity (159.46%) 784.09% (51.96%)
Return on assets (84.46%) (76.68%) (46.06%)
Return on invested capital (400.91%) 0.00% 0.00%

Growth

Metric ALGS IRLA Biotechnology median
Revenue growth (TTM) 1,171.58% — 6.76%
EPS growth (last fiscal year) 88.30% (28.24%) 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ALGS IRLA Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 1.77 14.52 4.97
Net debt to EBITDA 0.87 0.00 1.01

Dividend

Metric ALGS IRLA Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ALGS IRLA Biotechnology median
Market cap 28.17m 29.81m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack